Migraine
Conditions
Brief summary
This study will evaluate the bioequivalence of two solid dose formulations of MK0974.
Interventions
DRUGMK0974 Ethanolate formulation
Single dose MK0974 280 mg tablet in one of two treatment periods
DRUGComparator: MK0974 Hydrate formulation
Single dose MK0974 280 mg tablet in one of two treatment periods
Sponsors
Merck Sharp & Dohme LLC
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Subject is in good health * Subject is a non-smoker * Subject is willing to comply with the study restrictions
Exclusion criteria
* Subject has a history of stroke, chronic seizures, or major neurological disorder * Subject has a history of cancer * Subject is a nursing mother * Subject has or has a history of any disease or condition that might make participation in the study unsafe or that might confound the results of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area under the curve (AUC(0 to infinity) following single dose administration of MK0974 ethanolate or hydrate formulations | Through 48 hours postdose |
| Peak plasma concentration (Cmax) following single dose administration of MK0974 ethanolate or hydrate formulations | Through 48 Hours Post Dose |
Outcome results
None listed